Interestingly, pre-treatment of NK cells with idelalisib inhibited their production of inflammatory cytokines, such as TNFα and IFNγ but did not alter their ADCC against CLL cells (38) (Figure 3). The gene discussed is TNF; the disease is B-cell chronic lymphocytic leukemia.